Browse By Viral Diseases
This page shows data for Chickenpox disease.
Total
Entries Retrieved: 3
| ID | Vaccine Name | Disease Name | Disease Classification | Virus Name | Nucleic Acid Content | Vaccine Type | Vaccine Status | Manufacturer | Year of Manufacturing | Manufacturing Country | Age | Dosage | Administration Route | Adjuvant | Target Strain | Description | Approving Organisation | Collaborating Organisation | Other Countries | Trade Name | PMID | Clinical Trial ID | Reference Link | Additional Links |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10135 | Varivax | Chickenpox | Exanthous | Varicella-zoster virus | double stranded DNA | Live-attenuated | Approved | Merck & Co. Inc. | 2007 | USA | 1 - 12 years | 2 doses (0.5 ml each) separated by at least 3 months.# First dose: age 12 through 15 months, Second dose: age 4 through 6 years | Subcutaneous | NA | Oka/Merck strain of live-attenuated varicella virus | NA | US FDA | NA | NA | NA | NA | NCT00822237 | https://www.cdc.gov/vaccines/vpd/varicella/index.html | https://www.fda.gov/vaccines-blood-biologics/vaccines/varivax |
| 10136 | Varivax | Chickenpox | Exanthous | Varicella-zoster virus | double stranded DNA | Live-attenuated | Approved | Merck & Co. Inc. | 2007 | USA | 12 - 23 months | 2 doses 4 weeks apart | Subcutaneous | NA | Oka/Merck strain of live-attenuated varicella virus | NA | US FDA | NA | NA | NA | NA | NA | https://www.cdc.gov/vaccines/vpd/varicella/index.html | https://www.fda.gov/vaccines-blood-biologics/vaccines/varivax |